CAH's specialty growth, strong pharma demand and expanding services portfolio are driving earnings momentum and positioning it for sustained long-term growth.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

FNY Investment Advisers LLC bought a new stake in shares of Cardinal Health, Inc. (NYSE: CAH) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,000 shares of the company's stock, valued at approximately $822,000. Other hedge funds have also made changes to

CAH expands Ac-225 capacity, boosting its role in radiopharma as rising clinical demand and future cancer therapy commercialization drive growth.

CAH's specialty flywheel strategy links distribution, MSOs and biopharma services, boosting partnerships, drug launches and recurring revenue potential.

DUBLIN, Ohio, April 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for Theranostics Advancement (CTA) in Indianapolis, Indiana. The addition of a high-capacity production line to its Drug Master File (DMF) will substantially increase Cardinal Health's supply of cGMP-compliant Ac-225 for use in investigational therapeutic drug products and future commercial manufacturing novel therapies.

Burns Matteson Capital Management LLC lifted its position in shares of Cardinal Health, Inc. (NYSE: CAH) by 182.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,403 shares of the company's stock after buying an additional 3,492 shares during the period.

In the latest trading session, Cardinal Health (CAH) closed at $211.31, marking a +2.42% move from the previous day.

CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.